Pasar al contenido principal

MEJORA DE LA PREDICCION DE LOS PROCESOS NEURODEGENERATIVOS MEDIANTE EL USO DE GENETICA E IMAGENES CEREBRALES

PID2022-143106OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ BARCELONABETA BRAIN RESEARCH CENTER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 27
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment

  • Vilor Tejedor, Natalia
  • Rodrigo, Albert
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Anastasi, Federica
  • Pelkmans, Wiesje
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Adams, Hieab H.
  • Wisse, Laura
  • Gispert, Juan D.
  • Evans, Tavia E.|||0000-0003-2390-286X
The hippocampus, crucial in cognitive aging and Alzheimer's disease (AD), shows early atrophy during disease progression. This study investigated 5-year trajectories of hippocampal volumes across AD stages, focusing on genetic predisposition to AD, captured through the polygenic risk score for AD (PRS-AD) and APOE, and their impact on hippocampal atrophy. Analyzing data from 1,051 participants in the ADNI, we found that AD genetic risk accelerates a reduction in hippocampal volume, particularly in individuals with mild cognitive impairment (MCI). Effects were primarily driven by cerebrospinal fluid protein quantitative trait loci of APOE. Excluding the APOE region from analyses negated these effects, underscoring its critical role. This stage-specific effect suggested that AD genetic factors, particularly the APOE region, exert their influence primarily before or during the transition to MCI, highlighting the hippocampus's increased vulnerability during this period. These findings underscored the importance of targeting the MCI stage for early detection and intervention in AD. Further research is warranted to elucidate these dynamics and their potential clinical applications.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Brugulat Serrat, Anna, 1986-
  • Huguet, Jordi
  • Esteller, Manel
  • Sudre, Carole H.
  • Cortes-Canteli, Marta
  • Tristão Pereira, Catarina
  • Garcia-Lunar, Ines
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
Background: White matter hyperintensities (WMH) are a hallmark of cerebrovascular disease. They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. Although traditional cardiovascular risk factors are linked to WMH, some individuals with low vascular risk according to conventional scales still show WMH burden, suggesting an increased vulnerability. This study aimed to elucidate the biological mechanisms underlying the presence of WMH in cognitively unimpaired (CU) middle-aged and older individuals with low cardiovascular risk.Methods: We included 1,072 CU participants from the ALFA study with a low cardiovascular risk profile for late-life dementia (CAIDE-I score ≤ 9). We defined a multi-stage exploratory study design to reveal the potential biological pathways driving WMH in the study sample. First, we estimated the genetic predisposition to WMH using polygenic scoring (PRSWMH) and used this score as a predictor of: (a) WMHV as a subclinical quantitative measure of global and regional WMH burden and (b) pathological WMH levels (pathological: Fazekas score ≥ 2), as a qualitative measure of clinically relevant WMH. Covariate-adjusted Spearman’s rank correlation tests evaluated the association between the PRSWMH and regional and global WMH volumes (WMHV), while a logistic regression model was performed to explore the association with pathological WMH. Second, group-stratified partial correlations (CAIDE-specific factors) were explored to identify homogeneous groups with persistent genetic associations with WMH, beyond the presence of cardiovascular risk factors. Third, an enrichment analysis of the PRS-annotated genes unveiled the biological mechanisms leading to WMH burden. Finally, based on the enrichment analysis, we examined the role of cardiometabolic traits as biomarkers of WMHV.Results: Genetic predisposition to WMH was associated with larger global and regional WMHV after adjusting for age and sex, specifically in frontal areas. In this group, larger WMHV were associated with poorer executive function. Group-stratified analyses showed significant correlations particularly among older participants, those with hypercholesterolemia and those with lower educational attainment. Gene-set enrichment involved vascular, neuronal and cellular pathways, and blood pressure measurements partially mediated the association between the genetic risk for WMH and the actual WMHV.Interpretation: These findings support a polygenic contribution to cerebrovascular burden and nominate cardiac function as a biological link along the heart-brain axis. While the PRSWMH is not yet clinically actionable, our results propose and prioritize hemodynamic monitoring as an early, testable intervention in genetically susceptible individuals, to help prevent cerebrovascular damage and downstream cognitive impairment in healthy participants with low cardiovascular risk profile., The author(s) declare that financial support was received for the research and/or publication of this article. NV-T acknowledges support from the Ramón y Cajal Fellowship (RYC2022-038136-I) and the project PID2022-143106OA-I00, both funded by MCIN/AEI/10.13039/501100011033, with co-funding from FSE + and FEDER, EU, respectively. This work was also funded through the environMENTALment project (23S06083-001 to NV-T), supported by the Ajuntament de Barcelona and "la Caixa" Foundation. Additionally, NV-T received support from the Williams H. Gates Sr. AD Fellowship from the Alzheimer's Disease Data Initiative. IL was supported by the Instituto de Salud Carlos III (Project "PI24/00260," funded by Instituto de Salud Carlos III [ISCIII] and co-funded by the European Union).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Sex-specific early cognitive changes are linked to global and pathway-specific genetic risk for Alzheimer's disease in at-risk individuals

  • Genius, Patricia
  • Fernández-Bonet, Alba
  • Rodríguez-Fernández, Blanca
  • Gallay, Clara
  • González Escalante, Armand
  • Sánchez Benavides, Gonzalo
  • López-Martos, David
  • Esteller, Manel
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gispert, Juan Domingo
  • Brugulat Serrat, Anna, 1986-
  • Vilor Tejedor, Natàlia, 1988-
  • ALFA Study
Alzheimer's disease (AD) is a progressive neurodegenerative condition in which genetic predisposition plays a key role, yet the sex-specific mechanisms linking genetic risk to early cognitive changes remain unclear. This study examined the impact of polygenic risk scores (PRS) on early cognitive changes in 318 cognitively unimpaired participants from the ALFA+ cohort, a nested longitudinal cohort from the ALFA study (see details in Study Participants Section, Methods). Participants were followed for three years, with assessments across five cognitive domains and a preclinical composite (PACC). Global AD PRS, including and excluding the apolipoprotein E (APOE) gene, alongside five biologically informed pathway-specific PRS (amyloid, immune, external stimuli signaling, cholesterol efflux, lipoprotein metabolism) were computed. Generalized linear models including interaction by sex and stratified by sex and amyloid status (CSF Aβ42/40 < 0.071) assessed associations between PRS and cognitive change. In women, APOE-independent AD genetic risk predicted worse executive function, particularly via cholesterol efflux and external stimuli signaling pathways. Among Aβ + women, PRS also predicted lower memory performance, partially modulated by reproductive span. In Aβ - women, worse executive functioning performance was linked to amyloid, immune, and signaling pathways. In contrast, men showed associations between AD PRS and worse visual (Aβ-) and attentional (Aβ+) performance, independent of pathway-specific mechanisms. These findings reveal distinct, domain-specific cognitive vulnerabilities to AD genetic risk by sex and amyloid status, highlighting APOE-independent and mechanistic contributions to early and subtle cognitive changes. Results support the need for sex-aware, biologically informed genetic models in preclinical AD for risk stratification and early intervention., ABS receives funding from the Alzheimer's Association (AACSF-23-1145154). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER. Additionally, NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation.The ALFA+ study receives funding from "la Caixa" Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium

  • Luckett, Emma S.
  • Abakkouy, Yasmina
  • Lorenzini, Luigi
  • Collij, Lyduine E.
  • Vállez García, David
  • Visser, Pieter Jelle
  • den Braber, Anouk
  • Ritchie, Craig
  • Boada, Mercè
  • Genius, Patricia
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Vandenberghe, Rik
  • Barkhof, Frederik
  • Cleynen, Isabelle
  • AMYPAD Consortium
Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and EFPIA. F.B. and E.S.L. have received support for data curation and storage from the Alzheimer's Disease Data Initiative (ADDI; paid to institution). L.E.C. has acquired research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly), both paid to institution. L.E.C. is supported by the MSCA Postdoctoral fellowship (#101108819) and Alzheimer Association Research Fellowship (#23AARF-1029663) grants. N.V-T. receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, and grant PID2022-143106OA-I00 co-funded by the European Union FEDER). Additionally, N.V-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative, and grant 23S06083-001 funded by “la Caixa” Foundation and Barcelona City council. The F-PACK study was funded by the Stichting Alzheimer Onderzoek, Internal Funds KU Leuven, and Flemish Research Foundation (G0G1519N, G094418N), VLAIO (HBC.2019.2523, for R.V., Y.A., and I.C.). F.B. is supported by the NIHR biomedical research centre at UCLH.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Compositional brain scores capture Alzheimer's disease-specific structural brain patterns along the disease continuum

  • Genius, Patricia
  • Calle, M. Luz
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Cacciaglia, Raffaele
  • Garrido Martín, Diego, 1992-
  • Esteller, Manel
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Alzheimer&apos;s Disease Neuroimaging Initiative
  • ALFA Study
Introduction: Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain volumetric patterns to capture how Alzheimer's disease (AD) and genetics influence brain structure along the disease continuum. Methods: This study analyzed data from participants across the AD continuum from the Alzheimer's and Families (ALFA) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies. Compositional data analysis (CoDA) was exploited to examine relative brain volumetric variations that (1) were linked to different AD stages compared to cognitively unimpaired amyloid-β-negative (CU A-) individuals and (2) varied by AD genetic risk. Results: Disease stage-specific compositional brain scores were identified, differentiating CU A- individuals from those in more advanced stages. Genetic risk-stratified models revealed a broader genetic landscape affecting brain morphology in AD, beyond the well-known apolipoprotein E ε4 allele. Discussion: CoDA emerges as an alternative multivariate framework to deepen understanding of AD-related structural changes and support targeted interventions for those at higher genetic risk. Highlights: Compositional data analysis (CoDA) revealed the relative variation of brain region volumes, captured in compositional brain scores, capable of discerning between cognitively unimpaired amyloid-β-negative individuals and subjects within other disease-stage groups along the Alzheimer's disease (AD) continuum. CoDA also uncovered the genetic vulnerability of specific brain regions at each stage of the disease along the continuum. CoDA is capable of integrating magnetic resonance imaging data from two different cohorts without stringent requirements for harmonization. This translates as an advantage, compared to traditional methods, and strengthens the reliability of cross-study comparisons by standardizing the data despite different labeling agreements, facilitating collaborative and large-scale research. The algorithm is sensitive to AD-specific effects, as the main compositional brain scores display little overlap with the age-specific compositional brain score. CoDA provides a more accurate analysis of brain imaging data addressing its compositional nature, which can influence the development of targeted approaches, opening new avenues for enhancing brain health., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. N.V.-T. was supported by the Spanish Ministry of Science and Innovation—State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). In addition, N.V.-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. Data partially used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Advancing global dementia research through equity and inclusion

  • Vilor-Tejedor, Natalia
  • Danso, Samuel
  • Albanus, Ricardo D&apos;Oliveira
  • Billingsley, Kimberley
  • Evans, Tavia Emily
  • Lee, Liz Yuanxi
  • Wang, Selena
  • Jiang, Jiyang
  • Liu, Hangfan
  • Ross, Jermaine
  • Chilla, Geetha
Despite the global burden of dementia, research remains dominated by high-income, Western populations, limiting the generalizability and equity of findings. In this Perspective, we highlight the importance of diversity and inclusion in dementia research, not only in study participants but also in the researchers, study design, and funding priorities. We describe how the lack of representation creates knowledge gaps and delays progress in prevention, diagnosis, and treatment. We also present examples of initiatives that are working to change this, including the Alzheimer's Disease Data Initiative and the William H. Gates Sr. Fellowship program, which supports open science, international collaboration, and early-career researchers from underrepresented regions. These efforts demonstrate that diversity is not only an ethical goal, but a scientific need. More inclusive and global research could lead to discoveries that are more generalizable, more globally applicable, and better able to inform strategies to address dementia across all communities., We would like to thank the entire Alzheimer's Disease Data Initiative (ADDI) team for their invaluable support and collaboration throughout our fellowship. We are especially grateful to Caitlin Caitlin McHugh. Associate Director, Bioinformatics (Gates Ventures) for her guidance, coordination, and thoughtful input during the William H. Gates Sr. Fellowship, which greatly contributed to the successful completion of our projects and this work. All authors are supported by William H. Gates Sr. Fellowships from the Alzheimer's Disease Data Initiative. In addition, N.V-T. is supported by the Spanish Ministry of Science and Innovation-State Research Agency, grant RYC2022-038136-I. N.V-T is also co-funded by the European Union FSE+, grant PID2022-143106OA-I00, by the European Union FEDER, grant 23S06083-001, by the Ajuntament de Barcelona and 'la Caixa' Foundation, grant WE.08-2024-07, and by the AD Strategic Fund: Vascular Contributions to Cognitive Impairment and Dementia-Understanding Mechanisms of Dysfunction (grant #VCID-UMD-26-1514428). T.E.E. is additionally supported by the Alzheimer's Association Research postdoctoral fellowship 25AARF-1377279 (2025-2029), and Alzheimer Nederland project WE.03-2024-07 (2025-2027). K.J.B. is additionally supported in part by the Intramural Research Programs of the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), Department of Health and Human Services; project numbers Z01-AG000949, 1ZIANS003154. S.W. is additionally supported by NIA P30AG072976. H.L. is additionally supported in part by NIH grant R01AG081693. L.L.Y. is additionally supported by the Isaac Newton Trust.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Campo, Marta del
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project "PI19/00155" and "PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers

  • Cumplido-Mayoral, Irene
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • López-Martos, David
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Falcón, Carles
  • Cacciaglia, Raffaele
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
  • ADNI
Magnetic resonance Imaging (MRI)-derived brain-age prediction is a promising biomarker of biological brain aging. Accelerated brain aging has been found in Alzheimer's disease (AD) and other neurodegenerative diseases. However, no previous studies have investigated the relationship between specific pathophysiological pathways in AD and biological brain aging. Here, we studied whether glial reactivity and synaptic dysfunction are associated with biological brain aging in the earliest stages of the Alzheimer's continuum, and if these mechanisms are differently associated with AD-related cortical atrophy. We further evaluated their effects on cognitive decline. We included 380 cognitively unimpaired individuals from the ALFA+ study, for which we computed their brain-age deltas by subtracting chronological age from their brain age predicted by machine learning algorithms. We studied the cross-sectional linear associations between brain-age delta and cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction (neurogranin, GAP43, synaptotagmin-1, SNAP25, and α-synuclein), glial reactivity (sTREM2, YKL-40, GFAP, and S100b) and inflammation (interleukin-6). We also studied the cross-sectional linear associations between AD signature and these CSF biomarkers, We further evaluated the mechanisms linking baseline brain-age delta and longitudinal cognitive decline by performing mediation analyses. To reproduce our findings on an independent cohort, we included 152 cognitively unimpaired and 310 mild cognitive impaired (MCI) individuals from the ADNI study. We found that higher CSF sTREM2 was associated with a younger brain-age after adjusting for AD pathology, both in ALFA+ cognitively unimpaired and in ADNI MCI individuals. Furthermore, we found that CSF sTREM2 fully mediated the link between older brain-age and cognitive decline in ALFA+. In summary, we showed that the protective microglial state reflected by higher CSF sTREM2 has a beneficial impact on biological brain aging that may partly explains the variability in cognitive decline in early AD stages, independently of AD pathology., The study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and all participants gave written informed consent. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 009132017-SGR-892. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER); and from a fellowship from ”la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). DLM is supported by the project PI19/00117, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER). VV has been supported by the project PID2020-116907RB-I00, funded by the Ministry of Science and Innovation - State Research Agency, MCIN/ AEI /10.13039/501100011033. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III co-funded by the European Union (FEDER) (PI19/00117) and from Ministry of Science and Innovation - State Research Agency MCIN/ AEI /10.13039/501100011033 co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043417-I). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033, co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043216-I). In addition, NV-T receives funding from the Alzheimer’s Disease Data Initiative (ADDI) through the William H. Gates Sr. Fellowship program, and the PID2022-143106OA-I00 project, funded by MCIN/AEI /10.13039/501100011033 and co-funded by the European Union (FEDER). RC is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2021-125433OA-100 (co-funded by the European Union (FEDER)) and a Ramón y Cajal contract (RYC2021-031128-I, co-funded by the European Union «NextGenerationEU»/PRTR).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes

  • Tranfa, Mario
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Lorenzini, Luigi
Background: The accumulation of amyloid-β1-42 (Aβ1-42) peptides and phosphorylated-Tau181 (p-Tau181) tangles from the preclinical stages of Alzheimer's disease (AD) has led to a biological definition of the disease. However, among Aβ1-42-positive individuals, cognitive decline onset varies, and some never develop symptoms. Genetic influences on molecular pathways and their interactions with proteinopathy may underlie this heterogeneity. Leveraging data from a large sample of cognitively intact older adults in the European Prevention of Alzheimer Dementia (EPAD) cohort, we examined how AD-related pathophysiological changes (i.e., Aβ1-42 and p-Tau181), polygenic pathways and their interaction are associated with WM micro- and macrostructural properties. Methods: We selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ1-42 and p-Tau181 measurements available, full genotyping, and structural and diffusion MRI. Polygenic risk scores (PRSs) were computed using 85 AD-related genetic variants. These were mapped to their corresponding genes and, after excluding those belonging to the APOE locus, clustered by function into six pathway-specific PRSs (i.e., immune activation, signal transduction, inflammation, lipid, amyloid, and clearance pathways). Diffusion MRIs were processed through the fixel-based analysis framework to derive fiber density (FD) and fiber cross-section (FC) metrics, which were averaged within WM tracts. Linear models assessed the effects of AD-related pathophysiological changes, global and pathway-specific PRSs, and their interactions on FD and FC at both the tract and fixel levels. Models were corrected for multiple comparisons. Results: P-Tau181 was primarily associated with greater FD. The lipid pathway was associated with greater FD and FC, with these effects predominantly occurring in the left hemisphere, consistent with evidence of hemispheric dominance. The clearance pathway moderated the effect of Aβ1-42 on FD, with a positive slope in A + compared to A- individuals. The immune activation pathway moderated the effect of p-Tau181 on FD, with a negative slope in T + compared to T- individuals. Conclusions: Pathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways., This work was funded by EU/EFPIA Innovative Medicines Initiative (IMI) grant 115736; Horizon 2020 grant 115952. ESL has received support for data curation and storage from the Alzheimer’s Disease Data Initiative (ADDI; paid to institution). LEC’s salary is supported by a MSCA postdoctoral fellowship research grant (101108819) and the Alzheimer Association Research Fellowship (grant 23AARF-1029663). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER; NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation. AA was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). JMW is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Society and Alzheimer's Research UK), the British Heart Foundation, The Fondation Leducq Network on Perivascular Spaces and the Row Fogo Centre for Research into Small Vessel Diseases. HJMMM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106). LL receives funding from the MSCA postdoctoral fellowship (#101204296).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

  • Imam, Farhad
  • Anastasi, Federica
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
  • Global Neurodegeneration Proteomics Consortium (GNPC)
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research., We thank all GNPC V1 consortium members who helped support the creation of the V1 harmonized dataset. We thank the participants, their families as well as the cohorts, institutions and their dedicated staff who helped create this consortium. Funding for the majority of biosample analyses was provided by Gates Ventures and Johnson & Johnson. Funding for cohort creation, participant biosample collection and additional biosample analysis was provided by the following sources. ALLFTD data collection and dissemination was supported by the ALLFTD Consortium (U19: AG063911, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS)) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by NINDS and the National Center for Advancing Translational Sciences; LEFFTDS: U01 AG045390, funded by the NIA and the NINDS). Additional funding support was provided by the National Institutes of Health (NIH)-NIA for Frontotemporal Dementia: Genes, Images, and Emotions: P01 AG019724 and the UCSF Alzheimer’s Disease Research Center: P30 AG062422. Samples from the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the NIA, were used in this study. The ALLFTD proteomic data included in this paper were funded by a grant from Gates Ventures. Alzheimer and Families (ALFA) was supported by funding from the MCIN/AEI/10.13039/501100011033/FEDER, European Union, through the PID2023-153312OB-I00 project; the CaixaResearch Institute under the project titled DETEC-PK; and the RYC2023-043831-I grant, funded by MCIN/AEI/10.13039/501100011033 and the FSE+. Additional researchers receive funding from the JDC2022-049347-I grant, funded by MCIU/AEI/10.13039/501100011033, the European Union NextGenerationEU/PRTR, the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER), the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project SLD077/21/000001, Project ‘PI19/00155’ and ‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). The ALFA proteomic data included in this paper were funded by a grant from Gates Ventures. Stichting Alzheimer Nederland and Stichting VUmc provided funds for supporting Alzheimer Center Amsterdam infrastructure. Additionally, ZonMw Memorabel program project ‘PRODIA’, as part of the Deltaplan Dementie, and 2bike4alzheimer (Alzheimer Nederland) are acknowledged for funding this study for the generation of proteomics data for Amsterdam UMC. The baseline ABC-PD study (study period 2014–2017) was funded by a pre-competitive grant from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. The follow-up study (study period 2018–2020) was funded by a grant from the Michael J. Fox Foundation for Parkinson’s Research (grant no. 15227). Neither study sponsor was involved in collection, analysis and interpretation of data, writing of the report or decision to submit the manuscript for publication. Janssen Research and Development was only involved in study design of the baseline visit. Answer ALS was supported by NEALS Biofluid Repository, and Answer ALS collected, annotated and granted permission to use ALS biofluid samples. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Baltimore Longitudinal Study of Aging (BLSA) was supported by the Intramural Research Program (IRP) of the NIH-NIA. Banner Health was supported by Arizona ADRC and Arizona APOE grants from the NIA (P30 AG019610 and R01 AG069453), the state of Arizona, the Banner Alzheimer’s Foundation, the Sun Health Foundation, the Michael J. Fox Foundation and Gates Ventures. Work at Lund University was supported by the NIA (R01AG083740), the ERC (ADG-101096455), the Alzheimer’s Association (ZEN24-1069572 and SG-23-1061717), the GHR Foundation, the Swedish Research Council (2022-00775 and 2021-02219), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s Disease) at Lund University, the Swedish Alzheimer Foundation (AF-980907 and AF-994229), the Swedish Brain Foundation (FO2021-0293 and FO2023-0163), the Parkinson Foundation of Sweden (1412/22), the Cure Alzheimer’s Fund, the Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-O000028), the WASP and DDLS joint call for research projects (WASP/DDLS22-066), the Lilly Research Award Program, Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080 and 2022-Projekt0107). Additionally, this work was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant no. KAW 2020.0239), the Swedish Research Council (2024-03642), the NIA (U01 AG079847-02) and Gates Ventures. The CHARIOT-PRO study was funded by Johnson & Johnson, Merck, Takeda and Gates Ventures, and analysis was supported by the UKRI Future Leaders Fellowship (MR/S03532X/1 and MR/Y02012X/1) and the NIHR ARC Dementia Fellowship. The Emory ADRC participation was supported by the Emory Goizueta Alzheimer’s Research Disease Center (P50AG025688) and grants from Gates Ventures for the generation of proteomics data, and data collection was supported through funding by NIA grants R01AG053960, R01AG057911, R01AG061800, RF1AG057471, RF1AG057470, R01AG061800, R01AG057911 and R01AG057339. The Kansas ADRC participation was supported by the NIH (P30 AG072973, P30 AG072974 and R01 AG064227) and further supported by the Neil & Norma Hill Foundation, the Annemarie & Arturo Gandioli-Fumagalli Foundation, the Perpetual Foundation, the John Williams Endowment and the Hillcrest Foundation. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Knight ADRC participation was supported by grants from the NIH (R01AG044546, RF1AG053303, RF1AG058501 and U01AG058922), the Michael J. Fox Foundation, the Alzheimer’s Association Zenith Fellows Award (ZEN-22-848604), Gates Ventures and an anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444, P01AG03991 and P01AG026276. Additionally, this work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The Whitehall II study was supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (Y014154, R024227, S011676 and K013351) and the NIA (R01AG056477 and R01AG062553).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment

  • Vilor Tejedor, Natàlia, 1988-
  • Rodrigo, Albert
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Anastasi, Federica
  • Pelkmans, Wiesje
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Adams, Hieab H.
  • Wisse, Laura
  • Gispert, Juan Domingo
  • Evans, Tavia E.
  • ADNI
The hippocampus, crucial in cognitive aging and Alzheimer's disease (AD), shows early atrophy during disease progression. This study investigated 5-year trajectories of hippocampal volumes across AD stages, focusing on genetic predisposition to AD, captured through the polygenic risk score for AD (PRS-AD) and APOE, and their impact on hippocampal atrophy. Analyzing data from 1,051 participants in the ADNI, we found that AD genetic risk accelerates a reduction in hippocampal volume, particularly in individuals with mild cognitive impairment (MCI). Effects were primarily driven by cerebrospinal fluid protein quantitative trait loci of APOE. Excluding the APOE region from analyses negated these effects, underscoring its critical role. This stage-specific effect suggested that AD genetic factors, particularly the APOE region, exert their influence primarily before or during the transition to MCI, highlighting the hippocampus¿s increased vulnerability during this period. These findings underscored the importance of targeting the MCI stage for early detection and intervention in AD. Further research is warranted to elucidate these dynamics and their potential clinical applications., NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER. Additionally, NV-T is supported by the William H. Gates Sr. Fellowship Cohort I from the Alzheimer's Disease Data Initiative, and grant WE.08-2024-07 funded by Alzheimer Nederland. FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. TEE is supported by the Alzheimer Association Research postdoctoral fellowship 25AARF-1377279, Alzheimer Nederland project WE.03-2024-07, and William H. Gates Sr. Fellowship Cohort II from the Alzheimer's Disease Data Initiative. This project is partly supported by the National Computing Facilities Processing research programme which is financed by the Dutch Research Council (NWO) under the grant [2022.018].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Compositional brain scores capture Alzheimer's disease-specific structural brain patterns along the disease continuum

  • Genius, Patricia
  • Calle, M. Luz
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Cacciaglia, Raffaele
  • Garrido-Martín, Diego
  • Esteller, Manel
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Vilor-Tejedor, Natalia
[Introduction] Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain volumetric patterns to capture how Alzheimer's disease (AD) and genetics influence brain structure along the disease continuum., [Methods] This study analyzed data from participants across the AD continuum from the Alzheimer's and Families (ALFA) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies. Compositional data analysis (CoDA) was exploited to examine relative brain volumetric variations that (1) were linked to different AD stages compared to cognitively unimpaired amyloid-β–negative (CU A−) individuals and (2) varied by AD genetic risk., [Results] Disease stage–specific compositional brain scores were identified, differentiating CU A− individuals from those in more advanced stages. Genetic risk–stratified models revealed a broader genetic landscape affecting brain morphology in AD, beyond the well-known apolipoprotein E ε4 allele., [Discussion] CoDA emerges as an alternative multivariate framework to deepen understanding of AD-related structural changes and support targeted interventions for those at higher genetic risk., Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. N.V.-T. was supported by the Spanish Ministry of Science and Innovation—State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). In addition, N.V.-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment

  • Vilor-Tejedor, Natalia
  • Rodrigo, Albert
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Anastasi, Federica
  • Pelkmans, Wiesje
  • Navarro, Arcadi
  • Adams, Hieab H
  • Wisse, Laura
  • Gispert, Juan D
  • Evans, Tavia E
The hippocampus, crucial in cognitive aging and Alzheimer's disease (AD), shows early atrophy during disease progression. This study investigated 5-year trajectories of hippocampal volumes across AD stages, focusing on genetic predisposition to AD, captured through the polygenic risk score for AD (PRS-AD) and APOE, and their impact on hippocampal atrophy. Analyzing data from 1,051 participants in the ADNI, we found that AD genetic risk accelerates a reduction in hippocampal volume, particularly in individuals with mild cognitive impairment (MCI). Effects were primarily driven by cerebrospinal fluid protein quantitative trait loci of APOE. Excluding the APOE region from analyses negated these effects, underscoring its critical role. This stage-specific effect suggested that AD genetic factors, particularly the APOE region, exert their influence primarily before or during the transition to MCI, highlighting the hippocampus's increased vulnerability during this period. These findings underscored the importance of targeting the MCI stage for early detection and intervention in AD. Further research is warranted to elucidate these dynamics and their potential clinical applications., NV-T is supported by the Spanish Ministry of Science and Innovation – State Research Agency grant RYC2022-038136-I, co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER. Additionally, NV-T is supported by the William H. Gates Sr. Fellowship Cohort I from the Alzheimer’s Disease Data Initiative, and grant WE.08-2024-07 funded by Alzheimer Nederland. FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. TEE is supported by the Alzheimer Association Research postdoctoral fellowship 25AARF-1377279, Alzheimer Nederland project WE.03-2024-07, and William H. Gates Sr. Fellowship Cohort II from the Alzheimer’s Disease Data Initiative. This project is partly supported by the National Computing Facilities Processing research programme which is financed by the Dutch Research Council (NWO) under the grant [2022.018]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy

  • Timsina, Jigyasha
  • Pérez-Tur, Jordi
  • Bullido, María Jesús
  • Mir, Pablo
  • Navarro, Arcadi
  • Cruchaga, Carlos
24 páginas, 4 figuras, 3 tablas., Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer's disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Here, we perform a genome wide association study meta-analysis including 18,948 individuals of European ancestry and identify 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicate the association of biomarkers with APOE, CR1, GMNC/CCDC50 and C16orf95/MAP1LC3B. Novel loci include BIN1 for amyloid beta and GNA12, MS4A6A, SLCO1A2 with both total tau and phosphorylated tau 181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2. We also demonstrate that these variants have significant association with Alzheimer's disease risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent of APOE, coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation., We thank the Valdecilla Biobank (PT17/0015/0019), integrated into the Spanish BiobankNetwork, for their support and collaboration in sample collection and management. We want to acknowledge support from Moondance Dementia Research Laboratory. Spanish Institute of Health Carlos III (ISCIII). Also, the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, Instituto de Salud Carlos III (ISCIII), Acción Estratégica en Salud integrated in the Spanish National R + D + I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grants PI19/00335 and PI22/01403. The support of CIBERNED (ISCIII) under the grant CB18/05/00010. The support from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant No AC19/00097. The support of Fundación Bancaria “La Caixa”, Fundación ADEY, Fundación Echevarne and Grífols SA (GR@ACE project). A.C. received support from the ISCIII under the grant Sara Borrell (CD22/00125). P.G.G. is supported by CIBERNED employment plan (CNV-304-PRF-866). MB received funding from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. N°. 115985; PreDADQoL, ERA-NET (call 2015). Grant n° AC15/00082; TARTAGLIA (Red federada para accelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023-1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO,Grant N° PMP22/00022. Marta Marquié received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706 and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335. F.A. receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/ 501100011033 and the European Union NextGenerationEU/PRTR. N.V.-T. receives funding from the Spanish Research Agency MICIU/AEI/ 10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillon, Carolina
  • Brugulat-Serrat, Anna
  • Huguet, Jordi
  • Esteller, Manel
  • Sudre, Carole H
  • Cortés-Canteli, Marta
  • Tristão-Pereira, Catarina
  • García Lunar, Inés
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Vilor-Tejedor, Natalia
This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would have not been possible., Background: White matter hyperintensities (WMH) are a hallmark of cerebrovascular disease. They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. Although traditional cardiovascular risk factors are linked to WMH, some individuals with low vascular risk according to conventional scales still show WMH burden, suggesting an increased vulnerability. This study aimed to elucidate the biological mechanisms underlying the presence of WMH in cognitively unimpaired (CU) middle-aged and older individuals with low cardiovascular risk.Methods: We included 1,072 CU participants from the ALFA study with a low cardiovascular risk profile for late-life dementia (CAIDE-I score ≤ 9). We defined a multi-stage exploratory study design to reveal the potential biological pathways driving WMH in the study sample. First, we estimated the genetic predisposition to WMH using polygenic scoring (PRSWMH) and used this score as a predictor of: (a) WMHV as a subclinical quantitative measure of global and regional WMH burden and (b) pathological WMH levels (pathological: Fazekas score ≥ 2), as a qualitative measure of clinically relevant WMH. Covariate-adjusted Spearman’s rank correlation tests evaluated the association between the PRSWMH and regional and global WMH volumes (WMHV), while a logistic regression model was performed to explore the association with pathological WMH. Second, group-stratified partial correlations (CAIDE-specific factors) were explored to identify homogeneous groups with persistent genetic associations with WMH, beyond the presence of cardiovascular risk factors. Third, an enrichment analysis of the PRS-annotated genes unveiled the biological mechanisms leading to WMH burden. Finally, based on the enrichment analysis, we examined the role of cardiometabolic traits as biomarkers of WMHV.Results: Genetic predisposition to WMH was associated with larger global and regional WMHV after adjusting for age and sex, specifically in frontal areas. In this group, larger WMHV were associated with poorer executive function. Group-stratified analyses showed significant correlations particularly among older participants, those with hypercholesterolemia and those with lower educational attainment. Gene-set enrichment involved vascular, neuronal and cellular pathways, and blood pressure measurements partially mediated the association between the genetic risk for WMH and the actual WMHV.Interpretation: These findings support a polygenic contribution to cerebrovascular burden and nominate cardiac function as a biological link along the heart-brain axis. While the PRSWMH is not yet clinically actionable, our results propose and prioritize hemodynamic monitoring as an early, testable intervention in genetically susceptible individuals, to help prevent cerebrovascular damage and downstream cognitive impairment in healthy participants with low cardiovascular risk profile., The author(s) declare that financial support was received for the research and/or publication of this article. NV-T acknowledges support from the Ramón y Cajal Fellowship (RYC2022-038136-I) and the project PID2022-143106OA-I00, both funded by MCIN/AEI/10.13039/501100011033, with co-funding from FSE + and FEDER, EU, respectively. This work was also funded through the environMENTALment project (23S06083-001 to NV-T), supported by the Ajuntament de Barcelona and “la Caixa” Foundation. Additionally, NV-T received support from the Williams H. Gates Sr. AD Fellowship from the Alzheimer’s Disease Data Initiative. IL was supported by the Instituto de Salud Carlos III (Project “PI24/00260,” funded by Instituto de Salud Carlos III [ISCIII] and co-funded by the European Union)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sex-specific early cognitive changes are linked to global and pathway-specific genetic risk for Alzheimer's disease in at-risk individuals

  • Genius, Patricia
  • Fernández-Bonet, Alba
  • Rodríguez-Fernández, Blanca
  • Gallay, Clara
  • González Escalante, Armand
  • Sánchez Benavides, Gonzalo
  • López-Martos, David
  • Esteller, Manel
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gispert, Juan Domingo
  • Brugulat Serrat, Anna, 1986-
  • Vilor Tejedor, Natàlia, 1988-
  • ALFA Study
Alzheimer's disease (AD) is a progressive neurodegenerative condition in which genetic predisposition plays a key role, yet the sex-specific mechanisms linking genetic risk to early cognitive changes remain unclear. This study examined the impact of polygenic risk scores (PRS) on early cognitive changes in 318 cognitively unimpaired participants from the ALFA+ cohort, a nested longitudinal cohort from the ALFA study (see details in Study Participants Section, Methods). Participants were followed for three years, with assessments across five cognitive domains and a preclinical composite (PACC). Global AD PRS, including and excluding the apolipoprotein E (APOE) gene, alongside five biologically informed pathway-specific PRS (amyloid, immune, external stimuli signaling, cholesterol efflux, lipoprotein metabolism) were computed. Generalized linear models including interaction by sex and stratified by sex and amyloid status (CSF Aβ42/40 < 0.071) assessed associations between PRS and cognitive change. In women, APOE-independent AD genetic risk predicted worse executive function, particularly via cholesterol efflux and external stimuli signaling pathways. Among Aβ + women, PRS also predicted lower memory performance, partially modulated by reproductive span. In Aβ - women, worse executive functioning performance was linked to amyloid, immune, and signaling pathways. In contrast, men showed associations between AD PRS and worse visual (Aβ-) and attentional (Aβ+) performance, independent of pathway-specific mechanisms. These findings reveal distinct, domain-specific cognitive vulnerabilities to AD genetic risk by sex and amyloid status, highlighting APOE-independent and mechanistic contributions to early and subtle cognitive changes. Results support the need for sex-aware, biologically informed genetic models in preclinical AD for risk stratification and early intervention., ABS receives funding from the Alzheimer's Association (AACSF-23-1145154). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER. Additionally, NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation.The ALFA+ study receives funding from "la Caixa" Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Campo, Marta del
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project "PI19/00155" and "PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Compositional brain scores capture Alzheimer's disease-specific structural brain patterns along the disease continuum

  • Genius, Patricia
  • Calle, M. Luz
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Cacciaglia, Raffaele
  • Garrido Martín, Diego, 1992-
  • Esteller, Manel
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Alzheimer&apos;s Disease Neuroimaging Initiative
  • ALFA Study
Introduction: Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain volumetric patterns to capture how Alzheimer's disease (AD) and genetics influence brain structure along the disease continuum. Methods: This study analyzed data from participants across the AD continuum from the Alzheimer's and Families (ALFA) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies. Compositional data analysis (CoDA) was exploited to examine relative brain volumetric variations that (1) were linked to different AD stages compared to cognitively unimpaired amyloid-β-negative (CU A-) individuals and (2) varied by AD genetic risk. Results: Disease stage-specific compositional brain scores were identified, differentiating CU A- individuals from those in more advanced stages. Genetic risk-stratified models revealed a broader genetic landscape affecting brain morphology in AD, beyond the well-known apolipoprotein E ε4 allele. Discussion: CoDA emerges as an alternative multivariate framework to deepen understanding of AD-related structural changes and support targeted interventions for those at higher genetic risk. Highlights: Compositional data analysis (CoDA) revealed the relative variation of brain region volumes, captured in compositional brain scores, capable of discerning between cognitively unimpaired amyloid-β-negative individuals and subjects within other disease-stage groups along the Alzheimer's disease (AD) continuum. CoDA also uncovered the genetic vulnerability of specific brain regions at each stage of the disease along the continuum. CoDA is capable of integrating magnetic resonance imaging data from two different cohorts without stringent requirements for harmonization. This translates as an advantage, compared to traditional methods, and strengthens the reliability of cross-study comparisons by standardizing the data despite different labeling agreements, facilitating collaborative and large-scale research. The algorithm is sensitive to AD-specific effects, as the main compositional brain scores display little overlap with the age-specific compositional brain score. CoDA provides a more accurate analysis of brain imaging data addressing its compositional nature, which can influence the development of targeted approaches, opening new avenues for enhancing brain health., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. N.V.-T. was supported by the Spanish Ministry of Science and Innovation—State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). In addition, N.V.-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. Data partially used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes

  • Tranfa, Mario
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Lorenzini, Luigi
Background: The accumulation of amyloid-β1-42 (Aβ1-42) peptides and phosphorylated-Tau181 (p-Tau181) tangles from the preclinical stages of Alzheimer's disease (AD) has led to a biological definition of the disease. However, among Aβ1-42-positive individuals, cognitive decline onset varies, and some never develop symptoms. Genetic influences on molecular pathways and their interactions with proteinopathy may underlie this heterogeneity. Leveraging data from a large sample of cognitively intact older adults in the European Prevention of Alzheimer Dementia (EPAD) cohort, we examined how AD-related pathophysiological changes (i.e., Aβ1-42 and p-Tau181), polygenic pathways and their interaction are associated with WM micro- and macrostructural properties. Methods: We selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ1-42 and p-Tau181 measurements available, full genotyping, and structural and diffusion MRI. Polygenic risk scores (PRSs) were computed using 85 AD-related genetic variants. These were mapped to their corresponding genes and, after excluding those belonging to the APOE locus, clustered by function into six pathway-specific PRSs (i.e., immune activation, signal transduction, inflammation, lipid, amyloid, and clearance pathways). Diffusion MRIs were processed through the fixel-based analysis framework to derive fiber density (FD) and fiber cross-section (FC) metrics, which were averaged within WM tracts. Linear models assessed the effects of AD-related pathophysiological changes, global and pathway-specific PRSs, and their interactions on FD and FC at both the tract and fixel levels. Models were corrected for multiple comparisons. Results: P-Tau181 was primarily associated with greater FD. The lipid pathway was associated with greater FD and FC, with these effects predominantly occurring in the left hemisphere, consistent with evidence of hemispheric dominance. The clearance pathway moderated the effect of Aβ1-42 on FD, with a positive slope in A + compared to A- individuals. The immune activation pathway moderated the effect of p-Tau181 on FD, with a negative slope in T + compared to T- individuals. Conclusions: Pathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways., This work was funded by EU/EFPIA Innovative Medicines Initiative (IMI) grant 115736; Horizon 2020 grant 115952. ESL has received support for data curation and storage from the Alzheimer’s Disease Data Initiative (ADDI; paid to institution). LEC’s salary is supported by a MSCA postdoctoral fellowship research grant (101108819) and the Alzheimer Association Research Fellowship (grant 23AARF-1029663). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER; NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation. AA was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). JMW is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Society and Alzheimer's Research UK), the British Heart Foundation, The Fondation Leducq Network on Perivascular Spaces and the Row Fogo Centre for Research into Small Vessel Diseases. HJMMM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106). LL receives funding from the MSCA postdoctoral fellowship (#101204296).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium

  • Luckett, Emma S.
  • Abakkouy, Yasmina
  • Lorenzini, Luigi
  • Collij, Lyduine E.
  • Vállez García, David
  • Visser, Pieter Jelle
  • den Braber, Anouk
  • Ritchie, Craig
  • Boada, Mercè
  • Genius, Patricia
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Vandenberghe, Rik
  • Barkhof, Frederik
  • Cleynen, Isabelle
  • AMYPAD Consortium
Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and EFPIA. F.B. and E.S.L. have received support for data curation and storage from the Alzheimer's Disease Data Initiative (ADDI; paid to institution). L.E.C. has acquired research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly), both paid to institution. L.E.C. is supported by the MSCA Postdoctoral fellowship (#101108819) and Alzheimer Association Research Fellowship (#23AARF-1029663) grants. N.V-T. receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, and grant PID2022-143106OA-I00 co-funded by the European Union FEDER). Additionally, N.V-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative, and grant 23S06083-001 funded by “la Caixa” Foundation and Barcelona City council. The F-PACK study was funded by the Stichting Alzheimer Onderzoek, Internal Funds KU Leuven, and Flemish Research Foundation (G0G1519N, G094418N), VLAIO (HBC.2019.2523, for R.V., Y.A., and I.C.). F.B. is supported by the NIHR biomedical research centre at UCLH.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment

  • Vilor Tejedor, Natàlia, 1988-
  • Rodrigo, Albert
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Anastasi, Federica
  • Pelkmans, Wiesje
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Adams, Hieab H.
  • Wisse, Laura
  • Gispert, Juan Domingo
  • Evans, Tavia E.
  • ADNI
The hippocampus, crucial in cognitive aging and Alzheimer's disease (AD), shows early atrophy during disease progression. This study investigated 5-year trajectories of hippocampal volumes across AD stages, focusing on genetic predisposition to AD, captured through the polygenic risk score for AD (PRS-AD) and APOE, and their impact on hippocampal atrophy. Analyzing data from 1,051 participants in the ADNI, we found that AD genetic risk accelerates a reduction in hippocampal volume, particularly in individuals with mild cognitive impairment (MCI). Effects were primarily driven by cerebrospinal fluid protein quantitative trait loci of APOE. Excluding the APOE region from analyses negated these effects, underscoring its critical role. This stage-specific effect suggested that AD genetic factors, particularly the APOE region, exert their influence primarily before or during the transition to MCI, highlighting the hippocampus¿s increased vulnerability during this period. These findings underscored the importance of targeting the MCI stage for early detection and intervention in AD. Further research is warranted to elucidate these dynamics and their potential clinical applications., NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER. Additionally, NV-T is supported by the William H. Gates Sr. Fellowship Cohort I from the Alzheimer's Disease Data Initiative, and grant WE.08-2024-07 funded by Alzheimer Nederland. FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. TEE is supported by the Alzheimer Association Research postdoctoral fellowship 25AARF-1377279, Alzheimer Nederland project WE.03-2024-07, and William H. Gates Sr. Fellowship Cohort II from the Alzheimer's Disease Data Initiative. This project is partly supported by the National Computing Facilities Processing research programme which is financed by the Dutch Research Council (NWO) under the grant [2022.018].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers

  • Cumplido-Mayoral, Irene
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • López-Martos, David
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Falcón, Carles
  • Cacciaglia, Raffaele
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
  • ADNI
Magnetic resonance Imaging (MRI)-derived brain-age prediction is a promising biomarker of biological brain aging. Accelerated brain aging has been found in Alzheimer's disease (AD) and other neurodegenerative diseases. However, no previous studies have investigated the relationship between specific pathophysiological pathways in AD and biological brain aging. Here, we studied whether glial reactivity and synaptic dysfunction are associated with biological brain aging in the earliest stages of the Alzheimer's continuum, and if these mechanisms are differently associated with AD-related cortical atrophy. We further evaluated their effects on cognitive decline. We included 380 cognitively unimpaired individuals from the ALFA+ study, for which we computed their brain-age deltas by subtracting chronological age from their brain age predicted by machine learning algorithms. We studied the cross-sectional linear associations between brain-age delta and cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction (neurogranin, GAP43, synaptotagmin-1, SNAP25, and α-synuclein), glial reactivity (sTREM2, YKL-40, GFAP, and S100b) and inflammation (interleukin-6). We also studied the cross-sectional linear associations between AD signature and these CSF biomarkers, We further evaluated the mechanisms linking baseline brain-age delta and longitudinal cognitive decline by performing mediation analyses. To reproduce our findings on an independent cohort, we included 152 cognitively unimpaired and 310 mild cognitive impaired (MCI) individuals from the ADNI study. We found that higher CSF sTREM2 was associated with a younger brain-age after adjusting for AD pathology, both in ALFA+ cognitively unimpaired and in ADNI MCI individuals. Furthermore, we found that CSF sTREM2 fully mediated the link between older brain-age and cognitive decline in ALFA+. In summary, we showed that the protective microglial state reflected by higher CSF sTREM2 has a beneficial impact on biological brain aging that may partly explains the variability in cognitive decline in early AD stages, independently of AD pathology., The study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and all participants gave written informed consent. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 009132017-SGR-892. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER); and from a fellowship from ”la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). DLM is supported by the project PI19/00117, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER). VV has been supported by the project PID2020-116907RB-I00, funded by the Ministry of Science and Innovation - State Research Agency, MCIN/ AEI /10.13039/501100011033. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III co-funded by the European Union (FEDER) (PI19/00117) and from Ministry of Science and Innovation - State Research Agency MCIN/ AEI /10.13039/501100011033 co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043417-I). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033, co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043216-I). In addition, NV-T receives funding from the Alzheimer’s Disease Data Initiative (ADDI) through the William H. Gates Sr. Fellowship program, and the PID2022-143106OA-I00 project, funded by MCIN/AEI /10.13039/501100011033 and co-funded by the European Union (FEDER). RC is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2021-125433OA-100 (co-funded by the European Union (FEDER)) and a Ramón y Cajal contract (RYC2021-031128-I, co-funded by the European Union «NextGenerationEU»/PRTR).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Brugulat Serrat, Anna, 1986-
  • Huguet, Jordi
  • Esteller, Manel
  • Sudre, Carole H.
  • Cortes-Canteli, Marta
  • Tristão Pereira, Catarina
  • Garcia-Lunar, Ines
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
Background: White matter hyperintensities (WMH) are a hallmark of cerebrovascular disease. They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. Although traditional cardiovascular risk factors are linked to WMH, some individuals with low vascular risk according to conventional scales still show WMH burden, suggesting an increased vulnerability. This study aimed to elucidate the biological mechanisms underlying the presence of WMH in cognitively unimpaired (CU) middle-aged and older individuals with low cardiovascular risk.Methods: We included 1,072 CU participants from the ALFA study with a low cardiovascular risk profile for late-life dementia (CAIDE-I score ≤ 9). We defined a multi-stage exploratory study design to reveal the potential biological pathways driving WMH in the study sample. First, we estimated the genetic predisposition to WMH using polygenic scoring (PRSWMH) and used this score as a predictor of: (a) WMHV as a subclinical quantitative measure of global and regional WMH burden and (b) pathological WMH levels (pathological: Fazekas score ≥ 2), as a qualitative measure of clinically relevant WMH. Covariate-adjusted Spearman’s rank correlation tests evaluated the association between the PRSWMH and regional and global WMH volumes (WMHV), while a logistic regression model was performed to explore the association with pathological WMH. Second, group-stratified partial correlations (CAIDE-specific factors) were explored to identify homogeneous groups with persistent genetic associations with WMH, beyond the presence of cardiovascular risk factors. Third, an enrichment analysis of the PRS-annotated genes unveiled the biological mechanisms leading to WMH burden. Finally, based on the enrichment analysis, we examined the role of cardiometabolic traits as biomarkers of WMHV.Results: Genetic predisposition to WMH was associated with larger global and regional WMHV after adjusting for age and sex, specifically in frontal areas. In this group, larger WMHV were associated with poorer executive function. Group-stratified analyses showed significant correlations particularly among older participants, those with hypercholesterolemia and those with lower educational attainment. Gene-set enrichment involved vascular, neuronal and cellular pathways, and blood pressure measurements partially mediated the association between the genetic risk for WMH and the actual WMHV.Interpretation: These findings support a polygenic contribution to cerebrovascular burden and nominate cardiac function as a biological link along the heart-brain axis. While the PRSWMH is not yet clinically actionable, our results propose and prioritize hemodynamic monitoring as an early, testable intervention in genetically susceptible individuals, to help prevent cerebrovascular damage and downstream cognitive impairment in healthy participants with low cardiovascular risk profile., The author(s) declare that financial support was received for the research and/or publication of this article. NV-T acknowledges support from the Ramón y Cajal Fellowship (RYC2022-038136-I) and the project PID2022-143106OA-I00, both funded by MCIN/AEI/10.13039/501100011033, with co-funding from FSE + and FEDER, EU, respectively. This work was also funded through the environMENTALment project (23S06083-001 to NV-T), supported by the Ajuntament de Barcelona and "la Caixa" Foundation. Additionally, NV-T received support from the Williams H. Gates Sr. AD Fellowship from the Alzheimer's Disease Data Initiative. IL was supported by the Instituto de Salud Carlos III (Project "PI24/00260," funded by Instituto de Salud Carlos III [ISCIII] and co-funded by the European Union).